Miao Yi, Yadav Vikas, Shadrick William, Liu Jiuyu, Jenner Alexander R, Nichols Connie B, Gee Clifford, Schäfer Martin, Tenor Jennifer L, Perfect John R, Lee Richard E, Brennan Richard G, Washington Erica J
Department of Biochemistry, Duke University School of Medicine, Durham, North Carolina, USA.
Department of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, North Carolina, USA.
mBio. 2025 Aug 25:e0179525. doi: 10.1128/mbio.01795-25.
Infections caused by fungal pathogens such as and are associated with high mortality rates, partly due to limitations in the current antifungal arsenal. This highlights the need for antifungal drug targets with novel mechanisms of action. The trehalose biosynthesis pathway is a promising antifungal drug target because trehalose biosynthesis is essential for virulence in and and is also a mediator of fungal stress responses, such as thermotolerance. To exploit its untapped antifungal potentials, we screened the St. Jude 3-point pharmacophore library to identify small molecule inhibitors of the first enzyme in the trehalose biosynthesis pathway, trehalose-6-phosphate synthase (Tps1). Structure-guided optimization of a potent hit, SJ6675, yielded a water-soluble inhibitor named 4456dh. Employing biochemical, structural, and cell-based assays, we demonstrate that 4456dh inhibits Tps1 enzymatic activity, suppresses trehalose synthesis, and exerts a fungicidal effect. Notably, the structure of Tps1 in complex with 4456 reveals that 4456 occupies the substrate binding pocket. Importantly, 4456dh renders normally thermotolerant fungal pathogens unable to survive at elevated temperatures, which is critical as we investigate the emergence of fungi from the environment due to a warming climate. Overall, this work develops the water-soluble 4456dh as an early-stage antifungal drug that has a distinct mechanism of action compared to existing clinical antifungals.IMPORTANCEThe rise of fungal infections in recent years is alarming due to an increase in the vulnerable immunocompromised population, global temperature increase, and limited antifungal treatment options. One of the major hurdles in developing new drugs is the identification of fungal-specific antifungal drug targets due to highly conserved cellular machinery between fungi and humans. Here, we describe a small molecule inhibitor, 4456dh, of the trehalose biosynthesis pathway. This pathway is present in fungi but not in humans. Trehalose plays a critical role in stress responses such as thermotolerance in fungal pathogens and is essential for their virulence. We show that treatment with 4456dh blocks the production of trehalose and renders fungal cells inviable. Thus far, 4456dh is active against two fungal pathogens of critical importance, suggesting broad-spectrum activity.
由诸如[未提及具体真菌名称]等真菌病原体引起的感染与高死亡率相关,部分原因是当前抗真菌药物库存在局限性。这凸显了对具有新作用机制的抗真菌药物靶点的需求。海藻糖生物合成途径是一个有前景的抗真菌药物靶点,因为海藻糖生物合成对于[未提及具体真菌名称]的致病性至关重要,并且也是真菌应激反应(如耐热性)的介质。为了开发其尚未开发的抗真菌潜力,我们筛选了圣犹大3点药效团文库,以鉴定海藻糖生物合成途径中第一种酶——海藻糖-6-磷酸合酶(Tps1)的小分子抑制剂。对一种强效命中化合物SJ6675进行结构导向优化,得到了一种名为4456dh的水溶性抑制剂。通过生化、结构和基于细胞的实验,我们证明4456dh抑制Tps1酶活性,抑制海藻糖合成,并发挥杀菌作用。值得注意的是,Tps1与4456复合物的结构表明4456占据了底物结合口袋。重要的是,4456dh使通常耐热的真菌病原体在高温下无法存活,这在我们研究由于气候变暖真菌从环境中出现的情况时至关重要。总体而言,这项工作开发了水溶性的4456dh作为一种早期抗真菌药物,其作用机制与现有的临床抗真菌药物不同。
近年来真菌感染的增加令人担忧,原因是免疫功能低下的易感人群增加、全球气温上升以及抗真菌治疗选择有限。开发新药的主要障碍之一是由于真菌和人类之间细胞机制高度保守,难以确定真菌特异性抗真菌药物靶点。在此,我们描述了一种海藻糖生物合成途径的小分子抑制剂4456dh。该途径存在于真菌中但不存在于人类中。海藻糖在真菌病原体的应激反应(如耐热性)中起关键作用,并且对其致病性至关重要。我们表明用4456dh处理可阻断海藻糖的产生并使真菌细胞无法存活。到目前为止,4456dh对两种至关重要的真菌病原体具有活性,表明其具有广谱活性。